FOLH1 and prostate cancer: A similar concept of considering maximum BEDs to tumors and organs was used by Begum et al. for patients receiving radioligand therapy with 177Lu-prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer 35.